Non-volitional assessment of tibialis anterior force and architecture during critical illness

Bronwen Connolly PhD1, Matthew Maddocks PhD2, Victoria MacBean PhD1, William Bernal PhD3, Nicholas Hart PhD2, Philip Hopkins PhD4, Gerrard F Rafferty PhD1
1King’s College London, Division of Asthma, Allergy and Lung Biology, Department of Respiratory Medicine, UK, 2King’s College London, Department of Palliative Care, Cicely Saunders Institute, UK, 3Institute of Liver Studies, King’s College Hospital, London, UK, 3Lane Fox Respiratory Unit, Guy’s & St.Thomas’ NHS Foundation Trust, London, UK, 4Department of Critical Care, King’s College Hospital, London, UK

Acknowledgements

This study was supported by funding from the King’s Health Partners Challenge Fund (King’s Health Partners, London, UK), R121156. BC is supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Abstract word count 150

Manuscript word count 3534

Corresponding author for reprints
Dr Gerrard F Rafferty

Department of Respiratory Medicine
Second Floor, Cheyne Wing
King’s College Hospital

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as an ‘Accepted Article’, doi: 10.1002/mus.26049

This article is protected by copyright. All rights reserved.
Skeletal muscle in critical illness

Denmark Hill
London, SE5 9RS
Email: Gerrard.rafferty@kcl.ac.uk
Tel: +44 20 3299 2082
Fax: +44 203 299 3791

Running title

Skeletal muscle in critical illness

Ethical Publication Statement

We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Disclosure of Conflicts of Interest

None of the authors has any conflict of interest to disclose.

Keywords

Critical illness, muscle force, architecture, ultrasound, assessment
ABSTRACT

Non-volitional assessment of tibialis anterior force and architecture during critical illness

Introduction

Contemporaneous measures of muscle architecture and force have not previously been conducted during critical illness to examine their relationship with intensive care unit (ICU)-acquired weakness.

Methods

Ankle dorsiflexor muscle force (ADMF) using high frequency electrical peroneal nerve stimulation and skeletal muscle architecture via ultrasound were measured in 21 of adult, critically ill patients, 16 at ICU admission.

Results

Thirteen patients were measured on two occasions. Of these 10 measured at ICU admission demonstrated muscle weakness. Despite significant reductions in tibialis anterior (TA$_{CSA}$, $\Delta$=-88.5±78.8 mm$^2$, $p=0.002$) and rectus femoris (RF$_{CSA}$, $\Delta$=-126.1±129.1 mm$^2$, $p=0.006$) cross-sectional area between occasions, ADMF did not change (100HzAD (9.8 (8.0-14.4)kg vs. 8.6 (6.7-19.2)kg, $p=0.9$).

Discussion

Muscle weakness was evident at ICU admission. No further decrements were observed seven days later despite significant reductions in muscle size. These data suggest that not all ICU weakness is truly ‘acquired’, and questions our understanding of muscle function during critical illness.

Keywords

Critical illness, muscle force, architecture, ultrasound, assessment
INTRODUCTION

Peripheral skeletal muscle wasting is an acute insult of critical illness, and may contribute to the development of intensive care unit-acquired weakness (ICU-AW). Recent data from a longitudinal prospective cohort study of survivors of acute respiratory distress syndrome demonstrated that patients with ongoing ICU-AW at hospital discharge had worse 5 year survival than those without weakness. Ultrasound has increasingly been used to assess muscle function by measuring parameters of muscle architecture such as cross-sectional area (CSA) and echogenicity. Sequential measurements of CSA have previously demonstrated a reduction of almost 20% in muscle bulk in critically ill patients during the first ten days of ICU admission. Furthermore, when comparing ultrasound-derived echogenicity data (a machine-generated parameter) to histological specimens, echogenicity was reported to have a predictive capacity for development of myofiber necrosis, a clinically-relevant finding.

Such measurements of peripheral skeletal muscle architecture do not, however, provide information on contractile properties and force-generating capacity of muscle. Volitional manual muscle testing is restricted to patients sufficiently conscious to perform testing and cannot distinguish true loss of muscle strength from poor motivation and impaired cognition. In contrast non-volitional techniques involving electrical or magnetic motor nerve stimulation eliminate the limitations imposed by patient cooperation, motivation and the clinical environment. Non-volitional measurements of muscle contractility in critically ill patients have been reported for adductor pollicis, tibialis anterior, and quadriceps muscle groups albeit acquired using either the single twitch response or trains of up to four stimuli and therefore not reflecting true muscle strength. 100Hz electrical stimulation of the peroneal nerve is tolerable in healthy subjects and patients with chronic obstructive pulmonary disease (COPD) and, unlike other non-volitional techniques the evoked tetanic contraction force reflects true muscle strength, being equal to that
obtained during a maximal voluntary contraction. In addition, assessment of ankle dorsiflexor muscle force (ADMF) is minimally disruptive to patient position or treatment and therefore relatively easy to apply in the ICU environment.

The aim of this study was to measure the degree and trajectory of change in peripheral skeletal muscle strength in patients admitted to ICU by measuring ADMF, and its relationship with contemporaneous assessment of peripheral skeletal muscle (tibialis anterior) architecture.

METHODS

Ethics Approval

Ethical approval was granted (National Research Ethics Committee London – Camden & Islington, 13/LO/02630) and the study conformed to the standards set by the Declaration of Helsinki (1996). Written informed assent for participation was obtained from all participants’ nominated next of kin or medical consultant.

Study design and setting

The study was undertaken in three tertiary referral ICUs (Liver, Medical, Surgical) of a university teaching hospital. Measurements were performed in patients on two occasions, separated by seven days.

Participants

Adult (≥18 years) patients admitted to ICU and likely to require invasive mechanical ventilation for at least 48 hours and remain in the ICU for 7 days, were eligible for inclusion. Patients could be recruited at any point during ICU admission. Exclusion criteria included acute neurological diagnoses, chronic neuro- or myo-pathies, receipt of neuromuscular blocking agents, trauma injuries (precluding lower limb strength assessment) and pregnancy. The right leg was assessed unless
impaired by clinical factors at the time of initial testing. The same leg was used for reassessment. All patients received standard physical therapy during ICU admission, at the autonomous discretion of their treating therapist. Typically this involved functional mobilisation activities; electrical muscle stimulation and in-bed cycle ergometry were not employed.

**Ankle dorsiflexor muscle force**

The equipment has been described previously \(^{14,15}\); for full details see the Online Supplement (Section E1). Briefly, ADMF was measured using a bespoke testing device into which the distal lower leg was secured. ADMF elicited by supramaximal electrical stimulation of the common peroneal nerve was measured using a strain gauge attached to the underside of the device footplate. Force response to single twitch (TwAD) and 1second trains of electrical stimulation at 5, 10, 20, 30, 40, 50, 80 and 100Hz (100HzAD) were recorded. Stimulation at half maximal tetanic tension and the maximal relaxation rate (MRR) of the twitch response were determined. The mean±SD between-occasion coefficients of variation for TwAD and 100HzAD were 6.5±1.7% and 3.5±0.7% respectively.

**Ultrasound imaging of peripheral skeletal muscle**

Tibialis anterior (TA) and quadriceps rectus femoris (RF) muscle cross-sectional area, pennation angle, echogenicity and subcutaneous thickness were assessed by an experienced investigator (BC) using real-time B-mode ultrasound \(^{14,15}\). Ultrasound imaging techniques are summarised below with full details in the Online Supplement (Section E2)

**Tibialis anterior**

Images of TA cross-sectional area (TA\(_{CSA}\)), pennation angle (TA\(_{PA}\)), echogenicity (TA\(_{EI}\)) and subcutaneous thickness (TA\(_{SC\_thickness}\)) were acquired using a 2-6MHz curvilinear and 4-12MHz linear (pennation angle only) transducer (C6-2 and L12-4 respectively, Philips Sparq Ultrasound System, Philips Healthcare, MA, USA) from the superior aspect of the distal lower limb at a point one-third of
the distance from the tibial plateau to the lateral malleolus, with the participant semi-supine, the knee supported in passive extension and the foot supported in neutral 17-19. Oblique cross-sectional imaging was minimised by the operator using visual inspection to obtain the smallest cross-sectional area. Scanning depth of TA was set to where the deep margin of the muscle could be visualized between the tibia and fibula.

*Quadriceps rectus femoris*

Imaging of RF muscle architecture (RF<sub>CSA</sub>, RF<sub>EI</sub>, RF<sub>PA</sub>, RF<sub>SCthickness</sub>) was performed in a similar manner (Online Supplement, Section E2), with the quadriceps muscle measured at a point two-thirds of the distance from the anterior superior iliac spine and the superior patellar border. Visualisation of the femur was used to assist scanning depth. RF<sub>PA</sub> was imaged with the probe rotated 90°, and the average value from five individual fibre angles determined.

**STATISTICS**

Data were tested for normality and expressed as either mean±SD or median (IQR). Differences in ADMF and architecture parameters between testing occasions were determined with (Wilcoxon signed-rank tests.). Predicted values and cut-offs for 100HzAD were determined from a regression model derived in similarly aged healthy controls:<sup>14</sup> 100HzAD(kg) = 4.431 + -0.116age + 0.030 TA<sub>CSA</sub> - 0.389 if female. Muscle weakness in critically ill patients was defined as 1.645 residual standard deviations below the predicted value derived from 100HzAD responses from healthy subjects. Thresholds of losses in cross-sectional area exceeding 9.24%<sup>20</sup> and 3.48%<sup>18</sup> were used to define muscle wasting in RF and TA muscles respectively. Relationships between ADMF and TA muscle architecture were assessed using Spearman’s correlation analysis. A p value less than 0.05 was considered statistically significant. Data were analysed using SPSS (SPSS Inc, Chicago, IL, US) and GraphPad Prism (v6 for Windows, GraphPad, La Jolla, CA, US).
RESULTS

Participants

Twenty-five patients were recruited between June 2013 and July 2014. Three patients were unable to undergo testing due to clinical deterioration between recruitment and testing (n=1 death, n=1 post-tracheostomy procedure, n=1 post-extubation). One further patient was unable to complete assessment due to withdrawal of personal consultee advice. Of the remaining 21 patients enrolled, 16 underwent initial testing within 24 hours of ICU admission. Characteristics of the cohort are presented in Table 1. By the second testing occasion, 3 patients had died, 1 patient refused consent for ongoing participation, and in 4 patients a deterioration in clinical status precluded testing. Overall 13 patients were reassessed on the second occasion (10 (76.9%) with initial testing at ICU admission). All patients were intubated on the first testing occasion. Five of the 13 patients tested on the second occasion had been extubated but remained on the critical care unit.

Ankle dorsiflexor muscle force

No adverse events occurred during testing, and measurement of ADMF was feasible and well tolerated by all patients. In the overall cohort of 21 patients, TwAD and 100HzAD were 3.0(2.2-4.2)kg and 10.5(8.8-15.2)kg respectively. There was no difference in TwAD or 100HzD between patients recruited at or during ICU admission (Table 2). In the 13 patients with repeat measurements there was no change in TwAD, 100HzAD, or TwAD and 100HzAD normalised to TA_CSA, between testing occasions (Table 3, Figure 1). Complete force-frequency curves were obtained in all patients at initial testing and in 12/13 patients on the second testing occasion when one patient was measured at 100Hz only (Figure 2). Summary values for the whole cohort at initial and second testing occasions are shown in Figure 3. There was no difference in stimulation frequency for half-maximal tetanic contraction or MRR on the first testing occasion compared to the second.

Tibialis anterior and quadriceps rectus femoris muscle architecture
No differences in muscle architecture for TA and RF were observed between patients recruited at or during ICU admission (Table 2). In patients with repeat assessments (Table 3) it was not possible to measure RF muscle architecture in one patient on either day due to obesity, and RF<sub>Pa</sub> could not be accurately measured in four patients. Significant reductions were observed in both TA<sub>CSA</sub> between testing occasions, equivalent to overall percentage reductions of -9.6±9.5% and -17.2±15.5% respectively. Individual trajectories of change for both muscle groups are presented in the Online Supplement (Section E3).

Wasting, as defined above, was observed in 10/12 (83.3%) patients for RF and 10/13 (76.9%) patients for TA muscles between testing occasions. Wasting of both muscle groups was observed in eight patients, isolated wasting of RF in two patients and of TA in one patient. One patient did not demonstrate wasting in either muscle group. ADMF was compared between patients presenting with and without TA muscle wasting. No difference in measures of TwAD or 100Hz AD were evident (Online Supplement, Section E4). Presence of chronic comorbidity also did no differ between those patients with and without TA wasting. Significant reductions were observed in both RF muscle echogenicity and echogenicity standard deviation between testing occasions (Table 3). No other changes RF or TA muscle architecture echogenicity were observed.

**Relationships between ADMF and tibialis anterior muscle architecture**

Positive correlations were observed between TA<sub>CSA</sub> and RF<sub>CSA</sub> on testing occasion 1 (Spearman’s r=0.7, p=0.01) and 2 (Spearman’s r=0.6, p=0.045) (Online Supplement, Section E4). Only 100HzAD and TA<sub>CSA</sub> demonstrated a significant relationship on the second testing occasion (Spearman’s r=0.6, p=0.047; Online Supplement, Section E5). No other relationships were observed.

**Predicted weakness**
Using the previously described regression model, predicted values for 100HzAD were determined in 19 of the 21 patients of the main cohort (n=2 missing TA<sub>c</sub> data); observed 100HzAD was found to be significantly lower than predicted 100HzAD (Table 2), and weakness was evident in 16 (84.2%) patients. A similar pattern was evident when examining the 16 patients from the main cohort who were tested within 24 hours of ICU admission. Fourteen patients (same n=2 missing data) had significantly reduced 100HzAD compared to predicted (Table 2), with 12 patients demonstrating weakness.

Predicted 100HzAD values were also determined for the 13 patients assessed on both occasions. ADMF weakness was observed in 12 patients on testing occasion one and in 11 patients on occasion two. On both occasions 100HzAD was significantly lower than predicted.

**DISCUSSION**

In this study involving contemporaneous measures of muscle strength and architecture, significant ankle dorsiflexor muscle weakness was observed in critically ill patients on admission to ICU. Despite significant reductions in TA<sub>c</sub> during the critical illness course, no further decrements in ADMF were observed. Although changes in cross-sectional area were observed in both proximal (RF) and distal (TA) lower limb muscles, only RF showed changes in muscle quality.

Our data suggest antecedent decline in force-generating capacity prior to ICU admission. The reduced strength on ICU admission could therefore reflect a combination of the development of critical illness as well as the presence of chronic comorbidity. This, in combination with absence of further decline in muscle force during the admission period, challenges the commonly accepted term of ICU-acquired weakness. Certainly this presentation is a clinical diagnosis of exclusion following treatment of all identifiable causes including the ICU-admission diagnosis. Nonetheless weakness developing pre-ICU admission is also a feature. ‘Critical illness-associated weakness’ may
be a more reflective term; further investigation in larger cohorts of patients with varying degrees of pre-existing weakness would be valuable. These data also suggest that other mechanisms such as changes within the central nervous system resulting in impaired muscle recruitment and reduced volitional muscle strength could be important in explaining the profound impairment observed in many survivors of critical illness.  

We have confirmed previous findings of reduced muscle contractility in sedated and ventilated critically ill patients. Longitudinal, as well as cross-sectional, measurements were performed in the current study and most initial testing was undertaken on day one of ICU admission. Such measures allowed not only characterisation of the underlying level of muscle weakness at ICU admission but also the ongoing impact of ICU stay. Our data have demonstrated that the initial insult of critical illness on muscle force occurs early, possibly prior to hospitalisation, and does not continue to the same degree during the illness course. We cannot, however, exclude changes in muscle function that occurred immediately on entry to ICU prior to assessment of skeletal muscle function. We also observed no consistent relationship between peripheral skeletal muscle size and force at either time points of assessment. This could be as a result of a small sample size resulting in type II error, but also indicative of a limitation of the ultrasound technique.

Previous studies from this laboratory and others have demonstrated relationships between muscle size and strength in the knee extensor and ankle dorsiflexor muscles of COPD patients and age-matched control subjects. Nonetheless, muscle CSA does not fully account for variation in muscle strength. Although the current ultrasound findings mirror previously reported declines in such parameters in ICU patients, ultrasonographic evaluation of muscle architecture solely reflects morphological features. Therefore the effects on muscle CSA of changes in lean muscle mass which are thought to occur during ICU admission could be masked by intrinsic alterations in muscle properties including infiltration of fat, fibrous tissue or extracellular fluid. It is possible that
clinical procedures (sedation, neuromuscular blockade), immobilisation and altered fluid balance during the acute phase of critical illness lead to an overestimation of CSA on D1 and would also explain the significant reductions in muscle CSA that were observed between D1 and D7 of admission despite no change in muscle strength. Furthermore this could also explain why a significant relationship between ADMF and $TA_{CSA}$ was only observed at the second assessment, later in the ICU stay.

Despite significant reductions in $RF_{CSA}$ and $TA_{CSA}$ there were no reductions in $100HzAD$. Differential atrophy of lower limb muscles has been demonstrated during prolonged bed rest and the predominant slow twitch fiber profile of the TA compared to RF may result in different responses in muscle architecture to the critical illness process. Such changes do not however explain the absence of change in muscle strength despite reductions in $TA_{CSA}$. No changes were observed in TA echogenicity, half maximal tetanic tension or MRR between testing occasions, which may have been expected if substantial changes in muscle quality or muscle fiber composition had occurred. It is also noteworthy that although TwAD was similar to that reported previously by our group for healthy elderly adults of a comparable age, TwAD:100HzAD was also increased. Such data highlight the limitations of the 1Hz twitch technique.

Our cohort were a highly selected, non-sequential convenience sample determined by consultee assent and investigator availability. Whilst this limits generalisability, the cohort sizes were larger than any previous studies examining sequential changes in neuromuscular ultrasound properties in critically ill patients or that involved non-volitional assessment of skeletal muscle strength. Nonetheless we acknowledge the small sample may yield unexpected findings, and that only approximately two-thirds of the cohort underwent repeat testing. Half of the attrition was, however, due to unmodifiable reasons of patient death or lack of consent. These occurrences, in combination with deteriorating clinical status in some patients, serve to highlight the overall
challenges associated with studying this particular patient group. It is important to note that more than three-quarters of patients in the overall cohort, and those who underwent testing on both occasions, were recruited within 24 hours of ICU admission.

Animal studies have previously shown decrements in force generating capacity following prolonged immobilization \(^{39-41}\). Translating such findings to interpret our data is not straightforward. Unlike studies examining disuse atrophy in models employing healthy animals, the ICU patients studied were not fit and healthy prior to ICU admission and all had multiple comorbidities. The weakness observed at ICU admission most likely reflects the patients’ previous physical condition as well as any acute insult of critical illness necessitating ICU admission. Quadriceps contractility has been shown to be four times lower in ICU patients with pre-existing sickness compared to healthy subjects but only two times lower than COPD patients \(^{13}\). The subsequent lack of change in skeletal muscle strength may also reflect opposing effects of immobilization, resolution of critical illness, or the influence of physical activity, via voluntary or involuntary movements, or focused physical rehabilitation. The lack of change in 100HzAD may also have been due to a ‘floor effect’ and the inability of patients to weaken further i.e. given the already reduced baseline muscle strength further weakness was not possible. This was, however, a relatively small physiological study in a heterogeneous ICU population. Larger studies are therefore highly recommended to validate these findings and examine the magnitude and trajectory of change in muscle strength across differing phenotypes of critically ill patients. Nonetheless these data still question our knowledge around how muscle behaves in the context of critical illness across the spectrum of patients admitted to the ICU, and whether all patients truly ‘acquire’ weakness in the ICU.

Whilst the current study used the trace method to assess muscle echogenicity, Cartwright et al \(^{36}\) defined their ROI as a 2x2cm portion within the muscle, and Grimm et al \(^{42}\) adopted the Heckmatt grading scale. The trace method was adopted as it offered a standardised approach which reflects
changes across the entirety of muscles evaluated regardless of size and avoids sampling from adjacent muscle groups\textsuperscript{43}, and the influence of ROIs located in different portions of the muscle CSA image.\textsuperscript{44} In the current study, the same experienced investigator (BC) performed all ultrasound measurements. Further data are, however, required to determine the clinical relevance of echogenicity findings e.g. indicating myofiber necrosis\textsuperscript{5} as well as the significance of measures of CSA obtained early in critical illness.

We assessed changes in muscle composition, using echointensity analysis\textsuperscript{4} alongside measurement of CSA as reductions in lean muscle mass could be masked by infiltration of fat, fibrous tissue or extracellular fluid.\textsuperscript{27,4,26} Echointensity findings for TA and RF muscles differed to previously reported studies in critical care patients where changes analogous to mild muscle breakdown and disruption of normal muscle architecture akin to myopathy were noted\textsuperscript{36,42}, albeit these findings required muscle biopsy data for substantiation.

We applied muscle-specific thresholds for determining wasting of both TA\textsuperscript{18} and RF\textsuperscript{20} muscles, albeit only the latter were derived from a critically ill population. Nonetheless this approach reflects a more accurate method for classification, avoiding assumptions that peripheral skeletal muscle groups with differing location (either proximal or distal), fiber type composition and function demonstrate similar rates of wasting. Determining which peripheral muscle group best reflects patient status overall is unclear. Fiber type composition is not uniform across all muscle groups\textsuperscript{29} and this limits the assumption of extrapolating weakness in one muscle, to be representative of a generalised peripheral skeletal muscle weakness effect. Assessment of quadriceps function, might be considered more ‘functionally’ relevant\textsuperscript{13}, than tibialis anterior however the patient repositioning required to measure quadriceps twitch tension is not unsubstantial in contrast to that required to assess ADMF, which requires minimal patient disturbance. Volitional scores of global muscle strength such as the Medical Research Council Sum-score used to diagnose ICU-AW\textsuperscript{21}, also omit key
muscle groups important for upper limb function and dexterity such as the hand muscles. We defined weakness using a regression equation incorporating values of \( TACSA \), age and sex, determined in age-matched healthy subjects. The relationship between muscle cross-sectional area measured using ultrasound and strength has not been extensively investigated in critically ill patients. However, we recognise that under such circumstances, the disease pathology, severity of acute illness and influence of various medical interventions may result in the relationships between muscle size and strength observed in healthy subjects no longer being entirely valid in this patient population. We also reported data for healthy individuals to demonstrate acceptable levels of inter-occasion coefficients of variation and infer confidence in the ADMF technique. Acquiring such reliability data (either intra-observer, inter-observer or inter-occasion) may not be feasible in the critically ill patient population, where changes in clinical status would influence the results. This in turn, highlights that variance evident in 100HzAD in the current study must be related to the nature of the clinical condition of patients.

CONCLUSION

Reduced force-generating capacity was evident in critically ill patients even on day one of ICU admission. No further decrements in ADMF were observed after one week despite the presence of significant reductions in \( TACSA \). These data contribute to our understanding of the individual trajectories of change in peripheral skeletal muscle during critical illness and the potential mechanism underlying such changes. Whilst use of ultrasound offers a clinically useful tool for monitoring parameters of muscle architecture, these data fail to provide a true physiological assessment of the functional status of the muscle.

ABBREVIATIONS LIST

ICU-AW, intensive care unit-acquired weakness; ICU, intensive care unit; COPD, chronic obstructive pulmonary disease; CSA, cross-sectional area; ADMF, ankle dorsiflexor muscle force; TwAD, single
twitch ankle dorsiflexor force; 100HzAD, 100Hz ankle dorsiflexor force; MRR, maximum relaxation rate; TA\textsubscript{CSA}, tibialis anterior cross-sectional area; RF\textsubscript{CSA}, rectus femoris cross-sectional area; APACHE, acute physiology and chronic health evaluation; ROI, region of interest

REFERENCES


FIGURE LEGENDS

Figure 1. Change in ankle dorsiflexor force (100HzAD) between testing occasions (n=13). n=13 patients assessed on each occasion.

Figure 2. Individual force-frequency curves for patients assessed on first (n=13) and second (n=12) testing occasion. Left panel, n=13 first testing occasion; Right panel, n=12, second testing occasion.

Abbreviations: TwAD – single twitch ankle dorsiflexor muscle force

Figure 3. Force frequency responses of the ankle dorsiflexors with 1 s trains of supramaximal electrical peroneal nerve stimulation at 5-100Hz. Top panel shows an example trace, including single twitch response, and bottom panel the mean (SD) ankle dorsiflexor muscle force for critically ill patients measured at the first testing occasion (filled circles) and second testing occasion (open squares). Points at bars represent values for mean and standard deviation respectively. First testing
occasion, n=13, normalised ADMF (%100HzAD) per stimulation frequency: 5Hz, 30.6±14.1; 10Hz, 46.7±20.1; 20Hz, 68.8±21.0; 30Hz, 82.4±16.1; 40Hz, 85.3±18.9; 50Hz, 91.7±13.8; 80Hz, 93.3±13.7.

Second testing occasion, n=12, normalised ADMF (%100HzAD) per stimulation frequency: 5Hz, 33.4±12.6; 10Hz, 53.3±16.8; 20Hz, 72.1±20.8; 30Hz, 81.7±14.8; 40Hz, 88.2±10.7; 50Hz, 94.7±10.4; 80Hz, 98.7±5.4. *Abbreviations:* ADMF – ankle dorsiflexor muscle force

**AUTHOR CONTRIBUTIONS**

BC was responsible for study design, data acquisition, analysis and interpretation, and drafted and revised manuscript. MM contributed to data acquisition, analysis and interpretation. VM contributed to data acquisition. WB and PH facilitated data acquisition. NH contributed to data interpretation. GFR was responsible for conception and contributed to study design, data acquisition and interpretation and manuscript revision. All authors contributed to manuscript revision and agreed the final version for submission. BC and GFR act as the guarantors for the intellectual integrity of the work.
<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Whole cohort (n=21)</th>
<th>Patients recruited within 24 hours ICU admission (n=16)</th>
<th>Patients tested on both occasions (n=13)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>66.7±15.9</td>
<td>72.2±12.0</td>
<td>66.2±15.3</td>
</tr>
<tr>
<td>Sex (M:F)</td>
<td>20:1</td>
<td>15:1</td>
<td>12:1</td>
</tr>
<tr>
<td>Chronic co-morbidity*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiac</td>
<td>12 (57.1)</td>
<td>10 (62.5)</td>
<td>7 (53.8)</td>
</tr>
<tr>
<td>Respiratory</td>
<td>5 (23.8)</td>
<td>4 (25.0)</td>
<td>4 (30.8)</td>
</tr>
<tr>
<td>Liver</td>
<td>4 (19.0)</td>
<td>1 (6.3)</td>
<td>1 (7.7)</td>
</tr>
<tr>
<td>Renal</td>
<td>2 (9.5)</td>
<td>1 (6.3)</td>
<td>1 (7.7)</td>
</tr>
<tr>
<td>Other</td>
<td>5 (23.8)</td>
<td>5 (31.3)</td>
<td>5 (38.5)</td>
</tr>
<tr>
<td>APACHE II</td>
<td>23.1±5.7</td>
<td>23.6±6.2</td>
<td>21.9±6.5</td>
</tr>
<tr>
<td>SOFA score#</td>
<td>12.4±3.2</td>
<td>11.8±2.7</td>
<td>12.0±2.7</td>
</tr>
<tr>
<td>MOF#</td>
<td>19 (90.5)</td>
<td>16 (100.0)</td>
<td>12 (92.3)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>22.1 (21.2-23.1)</td>
<td>22.0 (21.2-23.7)</td>
<td>22.5 (21.4-23.1)</td>
</tr>
<tr>
<td>Admission category</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical</td>
<td>18 (85.7)</td>
<td>15 (93.8)</td>
<td>10 (76.9)</td>
</tr>
<tr>
<td>Surgical</td>
<td>3 (14.3)</td>
<td>1 (6.2)</td>
<td>3 (23.1)</td>
</tr>
<tr>
<td>ICU LOS (days)</td>
<td>13.0 (9.0-25.5)</td>
<td>12.0 (8.0-26.8)</td>
<td>12.0 (8.0-44.0)</td>
</tr>
<tr>
<td>Hospital LOS (days)^~</td>
<td>58.1±51.4</td>
<td>61.6±54.6</td>
<td>57.1±54.0</td>
</tr>
<tr>
<td>Survival</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICU</td>
<td>14 (66.7)</td>
<td>11 (68.8)</td>
<td>9 (69.2)</td>
</tr>
<tr>
<td>Hospital</td>
<td>12 (57.1)</td>
<td>9 (56.3)</td>
<td>9 (69.2)</td>
</tr>
</tbody>
</table>

Between testing occasions (n=13)

| MV (days) | 5.0±2.7 |
Skeletal muscle in critical illness

MOF (days)  7.0 (5.0-7.0)

SOFA score**  9.6±3.4

Pharmacotherapy (number of patients; days)

Inotropes  11; 4.4±2.4

Vasopressors  4; 0.0 (0.0-1.5)

Sedation  12; 5.0±1.8

Analgesia  12; 4.8±1.9

NMBA  0;

Steroids  0;

Renal replacement therapy  7 (53.8%)

Fluid balance (l)**  5.9±5.8

Blood glucose level (mg/dl))**  126.0±28.8

Insulin (IU)**  111.0 (91.5-262.0)

Creatinine (mg/dl)**  1.4 (1.0-2.0)

Blood urea nitrogen (mg/dl)**  30.0±14.3

Data reported as mean±SD, median (interquartile range) or n (%). *Chronic comorbidities reflect all comorbidities reported in patients, therefore sum exceeds cohort number. ^At ICU admission. ~Indicates post-ICU discharge hospitalisation. **SOFA score, blood glucose level, insulin, creatinine and urea are group average values of individual average daily values between testing occasions; fluid balance is the average individual cumulative fluid balance between testing occasions.

Abbreviations: APACHE = acute physiology and chronic health evaluation. SOFA = sequential organ failure assessment. MOF = multi-organ failure. BMI = body mass index. ICU = intensive care unit. LOS = length of stay. MV = mechanical ventilation. CVVHF = continuous venous-venous haemofiltration. NMBA = neuromuscular blocking agents
Table 2. Ankle dorsiflexor muscle force and peripheral skeletal muscle architecture in patients

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Recruited within 24 hours ICU (n=16)</th>
<th>Recruited after Day 1 of ICU (n=5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>TwAD (kg)</td>
<td>3.3 (2.6-4.3)</td>
<td>1.7 (1.2-10.4)</td>
</tr>
<tr>
<td>100HzAD (kg)</td>
<td>9.8 (8.9-16.0)</td>
<td>8.4 (2.4-12.5)</td>
</tr>
<tr>
<td>100HzAD_{pred} (kg)</td>
<td>20.67 (16.5-23.6) *</td>
<td>23.4 (19.5-27.4)</td>
</tr>
<tr>
<td>100HzAD_{pred} (%)</td>
<td>56.0 (44.1-63.8) *</td>
<td>30.5 (10.4-60.1)</td>
</tr>
<tr>
<td>TwAD/MRR (kg/s)</td>
<td>0.002 (0.002-0.003)</td>
<td>0.001 (0.0007-0.002)</td>
</tr>
<tr>
<td>TA_{CSA} (mm$^2$)</td>
<td>853.3 (704.3-1043.0)</td>
<td>824.7 (692.2-1082.0)</td>
</tr>
<tr>
<td>TA_{EI} (AU)</td>
<td>47.5 (42.0-51.8)</td>
<td>47.0 (29.7-49.0)</td>
</tr>
<tr>
<td>TA_{EIOD} (AU)</td>
<td>30.6 (27.8-33.4)</td>
<td>23.2 (18.2-35.2)</td>
</tr>
<tr>
<td>TA_{PA} (°)</td>
<td>7.5 (6.9-8.1)</td>
<td>6.9 (6.6-7.2)</td>
</tr>
<tr>
<td>TA_{SC} thickness (cm)</td>
<td>3.3 (2.6-4.3)</td>
<td>4.6 (3.1-5.4)</td>
</tr>
<tr>
<td>TwAD/TA_{CSA} (g/mm$^2$)</td>
<td>3.9 (2.8-5.1)</td>
<td>1.5 (1.2-17.0)</td>
</tr>
<tr>
<td>100HzAD/TA_{CSA} (g/mm$^2$)</td>
<td>13.4 (10.5-16.6)</td>
<td>11.4 (3.1-57.2)</td>
</tr>
<tr>
<td>TwAD/100HzAD</td>
<td>0.3 (0.2-0.4)</td>
<td>0.3 (0.2-0.4)</td>
</tr>
<tr>
<td>RF_{CSA} (mm$^2$)</td>
<td>638.2 (521.0-747.6)</td>
<td>628.8 (373.5-1051.0)</td>
</tr>
<tr>
<td>RF_{EI} (AU)</td>
<td>52.0 (43.5-59.4)</td>
<td>55.6 (48.4-59.6)</td>
</tr>
<tr>
<td>RF_{EIOD} (AU)</td>
<td>29.1 (24.8-34.4)</td>
<td>32.8 (23.4-33.7)</td>
</tr>
<tr>
<td>RF_{PA} (°)</td>
<td>7.6 (7.1-8.4)</td>
<td>7.5 (6.1-8.4)</td>
</tr>
<tr>
<td>RF_{SC} thickness (cm)</td>
<td>0.8 (0.6-1.0)</td>
<td>1.4 (0.8-1.8)</td>
</tr>
</tbody>
</table>

Data are presented as mean±standard deviation or median (interquartile range). *n=14 due to missing 100HzAD data (n=1) and missing TA_{CSA} data (n=1) for inputting into prediction equation. 100HzAD for n=15 patients, 9.8 (8.9-16.0)kg; significantly lower than predicted values (p=0.0001).

Abbreviations: TwAD = twitch ankle dorsiflexor force. 100HzAD = 100Hz ankle dorsiflexor flexor force. MRR = maximum relaxation rate. TA_{CSA} = tibialis anterior cross-sectional area. TA_{EIOD} = tibialis anterior echogenicity (standard deviation). TA_{PA} = tibialis anterior pennation angle. TA_{SC} thickness = tibialis anterior subcutaneous thickness. RF_{CSA} = rectus femoris cross-sectional area. RF_{EIOD} = rectus femoris echogenicity (standard deviation). RF_{PA} = rectus femoris pennation angle. RF_{SC} thickness = rectus femoris subcutaneous thickness.

John Wiley & Sons, Inc.
This article is protected by copyright. All rights reserved.
Table 3. Ankle dorsiflexor muscle force and peripheral skeletal muscle architecture on repeat occasions

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Testing occasion 1</th>
<th>Testing occasion 2</th>
<th>Δ</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>TwAD (kg)</td>
<td>2.9 (2.0-3.6)</td>
<td>3.0 (2.0-4.1)</td>
<td>0.5 (-0.9-1.1)</td>
<td>0.5</td>
</tr>
<tr>
<td>100HzAD (kg)</td>
<td>9.8 (8.0-14.4)</td>
<td>8.6 (6.7-19.2)</td>
<td>-1.1 (-3.9-4.6)</td>
<td>0.9</td>
</tr>
<tr>
<td>100HzADpred (kg)*</td>
<td>21.8 (17.9-26.6)</td>
<td>19.3 (14.8-24.1)</td>
<td>-2.9 (-4.4-1.6)</td>
<td>0.01</td>
</tr>
<tr>
<td>100HzADpred (%)</td>
<td>56.0 (43.2-64.1)</td>
<td>51.2 (34.7-77.7)</td>
<td>12.1 (-17.2-23.9)</td>
<td>0.6</td>
</tr>
<tr>
<td>TwAD/MRR (kg/s)</td>
<td>0.002±0.0008</td>
<td>0.002±0.0009</td>
<td>-0.0003±0.0009</td>
<td>0.2</td>
</tr>
<tr>
<td>TA_CSA (mm²)</td>
<td>921.8</td>
<td>800.8</td>
<td>-84.3 (-133.4--54.2)</td>
<td>0.005</td>
</tr>
<tr>
<td>(752.2-1055.0)</td>
<td>(678.8-961.1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TA_L (AU)</td>
<td>47.4 (39.3-51.4)</td>
<td>42.2 (39.1-52.6)</td>
<td>2.3 (-3.6-7.5)</td>
<td>0.5</td>
</tr>
<tr>
<td>TA_EISO (AU)</td>
<td>29.1 (26.1-32.1)</td>
<td>27.6 (24.4-33.1)</td>
<td>-0.2 (-2.0-4.0)</td>
<td>0.9</td>
</tr>
<tr>
<td>TA_PA (°)</td>
<td>7.1 (6.8-7.9)</td>
<td>7.1 (6.7-7.7)</td>
<td>-0.1 (-0.6-0.3)</td>
<td>0.7</td>
</tr>
<tr>
<td>TA_SCthickness (cm)</td>
<td>0.3 (0.3-0.4)</td>
<td>0.3 (0.2-0.5)</td>
<td>-0.02 (-0.06-0.1)</td>
<td>0.6</td>
</tr>
<tr>
<td>TwAD/TA_CSA (g/mm²)</td>
<td>3.5 (2.1-4.0)</td>
<td>3.9 (2.3-5.3)</td>
<td>0.8 (-0.5-2.0)</td>
<td>0.2</td>
</tr>
<tr>
<td>100HzAD/TA_CSA (g/mm²)</td>
<td>13.2 (10.5-16.4)</td>
<td>11.7 (8.9-20.0)</td>
<td>1.8 (-4.3-5.9)</td>
<td>0.8</td>
</tr>
<tr>
<td>TwAD:100HzAD</td>
<td>0.3 (0.2-0.4)</td>
<td>0.3 (0.2-0.4)</td>
<td>0.01 (-0.04-0.2)</td>
<td>0.2</td>
</tr>
<tr>
<td>RF_CSA (mm²)*</td>
<td>632.2 (511.4-837.3)</td>
<td>553.8 (394.6-621.1)</td>
<td>-95.75</td>
<td>0.0049</td>
</tr>
<tr>
<td>(199.9-48.8)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RF_L (AU)*</td>
<td>56.3 (50.6-61.3)</td>
<td>47.5 (41.5-58.2)</td>
<td>-5.9 (-14.8-1.7)</td>
<td>0.02</td>
</tr>
<tr>
<td>RF_EISO (AU)*</td>
<td>32.0 (29.1-34.9)</td>
<td>26.3 (23.6-29.9)</td>
<td>-5.3 (-10.5--0.8)</td>
<td>0.03</td>
</tr>
<tr>
<td>RF_PA (°)*</td>
<td>7.3 (7.0-8.0)</td>
<td>7.4 (6.3-8.2)</td>
<td>-0.2 (-0.8-0.9)</td>
<td>0.9</td>
</tr>
<tr>
<td>RF_SCthickness (cm)*</td>
<td>0.89 (0.62-1.21)</td>
<td>0.95 (0.74-1.19)</td>
<td>-0.02 (-0.12-0.29)</td>
<td>1.0</td>
</tr>
</tbody>
</table>

Data are presented as median (interquartile range). n=13. p values derived from Wilcoxon signed rank tests (non-parametric data) and represent differences between testing occasion 1 and 2. *n=12: complete rectus femoris muscle architecture data not acquired in one patient due to obesity and rectus femoris pennation angle not measurable in a further four patients due to poor quality images. **Observed values significantly reduced compared to predicted on both testing occasions; p=0.0002 (Testing occasion 1) and p=0.008 (Testing occasion 2).
Abbreviations: TwAD = twitch ankle dorsiflexor force. 100HzAD = 100Hz ankle dorsiflexor flexor force. MRR = maximum relaxation rate. TA = tibialis anterior cross-sectional area. TA(SD) = tibialis anterior echogenicity (standard deviation). TAa = tibialis anterior pennation angle. TA = tibialis anterior subcutaneous thickness. RF = rectus femoris cross-sectional area. RF(SD) = rectus femoris echogenicity (standard deviation). RFa = rectus femoris pennation angle. RF = rectus femoris subcutaneous thickness.
Change in ankle dorsiflexor force (100HzAD) between testing occasions (n=13)

259x194mm (300 x 300 DPI)
Individual force-frequency curves for patients assessed on first (n=13) and second (n=12) testing occasion.
Force frequency responses of the ankle dorsiflexors with 1 s trains of supramaximal electrical peroneal nerve stimulation at 5-100Hz

207x270mm (300 x 300 DPI)